Parenteral Nutrition in Palliative Cancer Care: Detrimental, Futile, or Beneficial?
Erik Torbjørn LøhreTora Skeidsvoll SolheimGunnhild JakobsenOla Magne VagnildhaugTerese Louise Schmidberger KarlsenRagnhild Hansdatter HabberstadTrude Rakel BalstadMorten ThronæsPublished in: Current oncology (Toronto, Ont.) (2024)
Palliative cancer care patients may live for a long time, but malnutrition worsens the prognosis. Parenteral nutrition (PN) is suitable for replenishing a calorie deficit, but its advantages and tolerance late in the cancer trajectory are debated. We examined symptom development in hospitalized patients with and without PN. A total of 21 palliative cancer care patients receiving PN and 155 palliative cancer care patients not receiving PN during hospitalization in a specialized unit were retrospectively compared. We studied symptom intensity at admission, symptom relief during the hospital stay, and survival. The patients had locally advanced or metastatic cancer, a mean age of 70 years, and their median ECOG performance status was III. Symptom burden at admission was similar in the compared groups. Symptom relief during hospitalization was also similar. However, patients already on PN at admission reported more nausea and patients receiving PN during hospitalization reported better nausea relief compared to patients not receiving this intervention. Overall median survival was less than two months and similar in the compared groups. Based on a limited number of observations and a suboptimal study design, we were not able to demonstrate an increased symptom burden for palliative cancer care patients receiving PN late in the disease trajectory.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- emergency department
- squamous cell carcinoma
- small cell lung cancer
- palliative care
- randomized controlled trial
- patient reported
- radiation therapy
- patient reported outcomes
- neoadjuvant chemotherapy
- high intensity
- rectal cancer
- papillary thyroid